|
|
 |
|
Management Biographies |
|
|
 |
|
|
LISA W. DEBERARDINE
Vice President, Strategic Planning
& Financial Forecasting
Schering-Plough Corporation
Kenilworth, New Jersey
Lisa W. DeBerardine is vice president, Strategic Planning & Financial Forecasting, for Schering-Plough Corporation. DeBerardine is responsible for the corporate planning and forecasting function and certain strategic projects.
DeBerardine joined Schering-Plough in 1985 and since that time has held positions of increasing responsibility in Research, Pharmaceutical Operations and Investor Relations. She was most recently staff vice president, Investor Relations.
Prior to joining Schering-Plough, DeBerardine held the position of research group leader for Chase Chemical Company.
DeBerardine holds a B.S. degree from Rutgers University College of Pharmacy, and a master's in business administration, finance, from Rutgers University.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
